https://www.selleckchem.com/pr....oducts/exatecan-mesy
Our case report and review of the literature suggest a possible protective effect of TKI therapy against COVID-19 in patients with CML. Our case report and review of the literature highlight the multifaceted response in chronic myeloid leukaemia (CML) patients to COVID-19 (respiratory symptoms, pancytopenia, severe haemolytic anaemia and haemophagocytic lymphohistiocytosis, disseminated erythematous papular skin rash).The rates of intensive care unit admission and mechanical ventilation support, and lengths of hospital stay we
Like
Comment
Share
